「The data from the EMPA-REG OUTCOME® trial indicate that empagliflozin may have the potential to slow progression of kidney disease and to lower cardiovascular risk among people with chronic…
舊金山–(美國商業資訊)–穆迪分析(Moody』s Analytics)欣然宣佈出版新書《IFRS9與CECL下的新減值模型》(The New Impairment Model under IFRS 9 and CECL,下文簡稱《新減值模型》)。這本新書由該公司董事總經理兼研究與建模部全球負責人章京撰寫和主編, Risk Books出版。穆迪分析的其他幾位專家也參與了本書的撰寫,其…